Spanios — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Spanios is a private, preclinical-stage biotech company developing a sophisticated platform of 3D patient-derived tumor organoids designed to recapitulate the human tumor microenvironment, including immune interactions. Its core COMPASS platform offers three progressively complex models, culminating in a dynamic system with physiological flow, aimed at de-risking and accelerating oncology drug discovery for partners. Operating on an efficacy-first model, the company positions itself as a service and platform provider to innovators, seeking to address a critical bottleneck in solid tumor research by improving preclinical predictability.

Oncology

Technology Platform

COMPASS platform: a suite of 3D Patient Derived Tumoroid (PDT) models with increasing complexity (COMPASS 1, 2, 3) that co-culture tumor epithelium, stroma, and immune cells (PBMCs) to maintain an intact tumor microenvironment (TME) and enable study of tumor-immune interactions.

Opportunities

The high failure rate in oncology drug development due to poor preclinical models creates a massive demand for more predictive tools.

Spanios's platform, which claims applicability to all solid tumors and drug modalities, positions it to capture a significant share of this growing market.

Successful validation could lead to lucrative partnerships with large pharma and biotechs eager to de-risk their pipelines.

Risk Factors

Key risks include the unproven clinical predictive value of its COMPASS platform against established models, the challenge of commercializing a novel platform in a cost-sensitive industry, and dependence on securing ongoing venture funding to sustain operations before achieving profitability.

Competitive Landscape

Spanios competes in the crowded market of advanced preclinical models, including other organoid companies, patient-derived xenograft (PDX) providers, and large contract research organizations (CROs) developing complex in vitro systems. Its differentiation hinges on the specific integration of a functional immune component and physiological flow in its top-tier model.

More companies in Cell & Gene Therapy →More companies in United States →